DSpace Repository

Effects of Ketoconazole on the Clinical Recovery in Central Serous Chorioretinopathy

Show simple item record

dc.contributor.author Chantarasorn Y.
dc.contributor.author Rasmidatta K.
dc.contributor.author Pokawattana I.
dc.contributor.author Silpa-Archa S.
dc.date.accessioned 2022-12-14T03:16:56Z
dc.date.available 2022-12-14T03:16:56Z
dc.date.issued 2022
dc.identifier.issn 11775467
dc.identifier.uri https://www.scopus.com/inward/record.uri?eid=2-s2.0-85132763684&doi=10.2147%2fOPTH.S368427&partnerID=40&md5=d29fe9803675c9c3005d7dbe722d1c64
dc.identifier.uri https://ir.swu.ac.th/jspui/handle/123456789/27146
dc.description.abstract Purpose: Patients with hypercortisolism have been associated with a higher prevalence of the pachychoroid spectrum including central serous chorioretinopathy (CSCR), which may explain the inconsistency of therapeutic responses of the mineralocorticoid receptor antagonist because hyperaldosteronism has rarely been detected in patients with CSCR. Therefore, this study aimed to evaluate the effects of ketoconazole, the first-line cortisol inhibitor, on the resolution of subretinal fluid (SRF) in CSCR and to analyze correlations between choroidal thickness and steroid hormones. Patients and Methods: This retrospective cohort study included 41 naïve CSCR eyes of 41 patients categorized into control (20 eyes) and treatment (21 eyes) groups. Patients in the treatment group were administered oral ketoconazole at a daily dose of 400 or 600 mg for 3–6 weeks. At week 12, rescue laser therapy was applied to patients exhibiting persistent SRF. Thus, a survival analysis was performed to determine the time interval from presentation to clinical resolution of SRF. Secondary outcomes consisted of eyes with persistent SRF and factors affecting the therapeutic response. Results: The mean 24-hour urinary free cortisol (UFC) levels were elevated at 181 ± 70 and 150 ± 68 µg/day (range: 20–150) in the treatment and control groups, respectively (p = 0.21). After controlling for age and gender, baseline UFC levels were significantly associated with choroidal thickness in both eyes (p < 0.05). Ketoconazole significantly increased the CSCR resolution with the median time to resolution of 7 vs 16 weeks (p < 0.01) and decreased the proportion of eyes receiving rescue therapy at 12 weeks (23.8% vs 50%; p = 0.01). Prolonged CSCR durations were likely found in elderly patients with thick choroids in fellow eyes. Conclusion: Patients with CSCR showed elevated glucocorticoids, which further correlated with their choroidal thickness. Using cortisol blockers may shorten the duration of existing SRF. © 2022 Chantarasorn et al.
dc.language en
dc.publisher Dove Medical Press Ltd
dc.subject choroidal thickness
dc.subject cortisol
dc.subject mineralocorticoid receptor antagonist
dc.subject pachychoroidopathy
dc.title Effects of Ketoconazole on the Clinical Recovery in Central Serous Chorioretinopathy
dc.type Article
dc.rights.holder Scopus
dc.identifier.bibliograpycitation Songklanakarin Journal of Science and Technology. Vol 44, No.4 (2022), p.929-935
dc.identifier.doi 10.2147/OPTH.S368427


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account

Statistics